Product Information
BELSOMRA 5 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $15.2013 per EA under NDC 00006000530. Its NADAC has been published 568 times since Nov 18, 2015.
FDA first approved this application on Aug 13, 2014.
Strength
5 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006000530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUVOREXANTApproval Type
New Drug (NDA)
FDA Application
NDA204569FDA Approved
8/13/2014
On Market Since
8/29/2014
Pharmacological Classes
Price Statistics
The NADAC for BELSOMRA 5 MG TABLET has been published 568 times since Nov 18, 2015, and over the history we have for it it has risen 80.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.2013 per EA |
|---|---|
| All-time high | $15.2329 (May 13, 2026) |
| All-time low | $8.4294 (Dec 23, 2015) |
| 52-week high | $15.2329 |
| 52-week low | $14.8689 |
| Median price | $12.2906 |
| Average price | $12.1792 |
| Largest weekly change | +8.0% (Jan 17, 2018) |
| Weeks tracked | 568 |
| Tracking since | Nov 18, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the suvorexant market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
suvorexant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Orexin Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BELSOMRA 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BELSOMRA 5 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $15.2013 per EA (NDC 00006000530), effective Sep 30, 2026.
How has the price of BELSOMRA 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BELSOMRA 5 MG TABLET has risen 80.2%. It has been tracked across 568 weekly CMS publications since Nov 18, 2015.
What are the highest and lowest recorded NADAC prices for BELSOMRA 5 MG TABLET?
Since Nov 18, 2015, the NADAC for BELSOMRA 5 MG TABLET has ranged from a low of $8.4294 (Dec 23, 2015) to a high of $15.2329 (May 13, 2026), with a median of $12.2906 per EA.
Are there cheaper alternatives to BELSOMRA 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BELSOMRA 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BELSOMRA 5 MG TABLET?
BELSOMRA 5 MG TABLET (NDC 00006000530) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.